Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis

CONCLUSIONS: Molnupiravir does not decrease mortality and hospitalization rates in immunized patients with COVID-19. However, it does shorten the disease course and increases the recovery rate. The use of molnupiravir will need to be considered on a case-by-case basis in the context of the prevailing social circumstances, the resource setting, drug costs, and the healthcare burden.PMID:38555274 | DOI:10.1016/j.jmii.2024.03.002

Source: Journal of Microbiology, Immunology, and Infection - March 30, 2024 Category: Microbiology Authors: Huzaifa Ahmad Cheema Saleha Abdul Rab Momina Butt Uzair Jafar Abia Shahid Aqeeb Ur Rehman Ka Yiu Lee Syeda Sahra Ranjit Sah Source Type: research